AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Glimitoss M 3mg/500mg Tablet SR

Prescription Icon
Prescription Required

Marketer

Minitoss Medicines

Salt Composition

Glimepiride (3mg) + Metformin (500mg)

Overview Glimitoss M 3mg/500mg Tablet SR

Diabexe Duo 3mg/500mg Extended-Release Tablets are classified as antidiabetic agents. This dual-action medication treats type 2 diabetes in adults by regulating blood glucose. Diabexe Duo should be ingested with food, consistently at the same time daily for optimal efficacy. Dosage is determined by your physician and may be adjusted based on your blood sugar response. Continued use is vital, even with controlled blood sugar, as abrupt cessation can lead to elevated glucose levels, increasing the risk of complications including nephropathy, retinopathy, neuropathy, and peripheral vascular disease. Remember, this medication complements a comprehensive diabetes management plan encompassing a balanced diet, regular physical activity, and weight management as directed by your doctor. Lifestyle choices significantly impact diabetes control. Hypoglycemia (low blood sugar) is the most prevalent side effect, characterized by sweating, dizziness, headache, and tremors. Regular meals and readily available glucose sources (e.g., sugary snacks, fruit juice) are crucial for prevention. Alcohol consumption elevates hypoglycemia risk and should be minimized. Additional potential side effects include altered taste perception, nausea, diarrhea, abdominal discomfort, cephalgia, and upper respiratory infections. Weight gain may occur in some patients. This medication is contraindicated in individuals with type 1 diabetes, diabetic ketoacidosis, or severe hepatic or renal impairment. Prior heart conditions should be disclosed to your physician before commencing treatment. Pregnant or lactating women must consult their doctor. Regular blood glucose monitoring, along with periodic blood tests to assess blood cell counts and liver function, are recommended.

Uses of Glimitoss M 3mg/500mg Tablet SR

Managing type 2 diabetes

Major Benefits of Glimitoss M 3mg/500mg Tablet SR:

Administer this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Consume Glimitoss M 3mg/500mg Sustained-Release Tablet with food.

Common Side effects of Glimitoss M 3mg/500mg Tablet SR:

  • Headache
  • Hypoglycemia (low blood glucose level)
  • Nausea
  • Diarrhea

How to use Glimitoss M 3mg/500mg Tablet SR:

Administer this medication precisely as directed by your physician, adhering to the prescribed dosage and timeframe. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Consume Glimitoss M 3mg/500mg Extended-Release tablets with a meal.

How Glimitoss M 3mg/500mg Tablet SR works:

Glimitoss M 3mg/500mg Extended-Release tablets contain glimepiride and metformin, two antidiabetic agents. Glimepiride, a sulfonylurea, stimulates pancreatic insulin secretion to reduce blood sugar. Metformin, a biguanide, acts by decreasing hepatic glucose production, slowing intestinal glucose uptake, and enhancing insulin responsiveness.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Concurrent use of alcohol and Glimitoss M 3mg/500mg Tablet SR is inadvisable.

PregnancyPregnancyCONSULT YOUR DOCTOR

The use of Glimitoss M 3mg/500mg SR tablets during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to the fetus. A physician will assess the advantages against possible risks prior to prescribing. Seek medical advice.

Breast feedingBreast feedingUNSAFE

Prolonged-release Glimitoss M 3mg/500mg tablets are contraindicated for breastfeeding mothers. Evidence indicates potential infant harm from the medication.

DrivingDrivingCAUTION

Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.

KidneyKidneyCAUTION

Exercise caution when administering Glimitoss M 3mg/500mg SR tablets to individuals with impaired kidney function; dosage modification may be necessary. Consult a physician for guidance. For patients exhibiting severe kidney disease, Glimitoss M 3mg/500mg SR tablets are contraindicated. Close monitoring of renal function is recommended during treatment.

LiverLiverCAUTION

Patients with liver impairment should use Glimitoss M 3mg/500mg SR tablets cautiously, potentially requiring dosage modification. Consultation with a physician is advised. For those with mild to moderate liver disease, initiation should be at a low dose; the medication is contraindicated in patients with severe hepatic dysfunction.

What if you forget to take Glimitoss M 3mg/500mg Tablet SR :

Should you forget to take a Glimitoss M 3mg/500mg SR Tablet, administer it at your earliest convenience. Nevertheless, if your next scheduled dose is imminent, omit the missed tablet and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Glimitoss M 3mg/500mg Tablet SR

LabelValue
Developing Habits No.
Type of Treatment Diabetes Management

FAQs on Glimitoss M 3mg/500mg Tablet SR

Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication; keep it out of reach of children, pets, and others.
Glimitoss M 3mg/500mg Tablet SR can cause lactic acidosis, a serious medical emergency resulting from excess blood lactic acid (also known as Metformin-associated lactic acidosis or MALA). This rare but dangerous side effect is more likely in patients with kidney disease, older adults, or those who consume excessive alcohol. Symptoms include muscle pain or weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, discontinue Glimitoss M 3mg/500mg Tablet SR and seek immediate medical attention.
Glimitoss M 3mg/500mg SR tablets combine glimepiride and metformin to manage type 2 diabetes mellitus in adults. This combination improves blood sugar control when used with diet and exercise. Glimepiride stimulates insulin release from the pancreas, while metformin reduces liver glucose production and enhances insulin sensitivity. It's not suitable for type 1 diabetes.
Glimitoss M 3mg/500mg SR tablets may cause common side effects such as hypoglycemia, altered taste, nausea, stomach pain, diarrhea, and headache. Rare but serious side effects, including lactic acidosis, are also possible. Prolonged use can result in vitamin B12 deficiency.
Prolonged use of Glimitoss M 3mg/500mg SR tablets can lead to Vitamin B12 deficiency by hindering its absorption in the stomach. This deficiency may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, and balance problems), urinary issues, and cognitive changes. To mitigate these risks, supplemental Vitamin B12 intake, at least annually, is recommended by some researchers.
Glimitoss M 3mg/500mg SR Tablets can cause low blood sugar (hypoglycemia), manifesting as nausea, headache, irritability, hunger, sweating, dizziness, rapid heartbeat, anxiety, or shakiness. This risk increases with skipped meals, alcohol consumption, excessive exercise, or concurrent use of other diabetes medications. Regular blood sugar monitoring is crucial. Always carry a fast-acting sugar source, such as glucose tablets, honey, or fruit juice.
Combining Glimitoss M 3mg/500mg SR tablets with alcohol is unsafe. This combination may cause dangerously low blood sugar (hypoglycemia) and increase the risk of lactic acidosis.
Glimitoss M 3mg/500mg Tab...
60
MRP 70
14% off